# Mercadolibre Inc: financial statements, quarterly

MELI · Nasdaq · CIK 1099590 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/meli.md) · [Financials](/companies/meli/financials.md) · [Filings](/companies/meli/filings.md) · [Insiders](/companies/meli/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/meli/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,709](/filings/0001099590-24-000042.md) | [4,409](/filings/0001099590-24-000042.md) | [3,099](/filings/0001099590-25-000028.md) | [3,765](/filings/0001099590-25-000044.md) | [3,895](/filings/0001099590-25-000051.md) | [4,436 d](/filings/0001099590-26-000006.md) | [4,191](/filings/0001099590-26-000017.md) | [4,803](/filings/0001099590-26-000023.md) | [5,205](/filings/0001099590-25-000051.md) | [6,136 d](/filings/0001099590-26-000006.md) | [6,065](/filings/0001099590-26-000017.md) | [7,055](/filings/0001099590-26-000023.md) |
| Cost of revenue | $m | [1,832](/filings/0001099590-24-000042.md) | [2,359](/filings/0001099590-24-000042.md) | [2,309](/filings/0001099590-25-000028.md) | [2,708](/filings/0001099590-25-000044.md) | [2,873](/filings/0001099590-25-000051.md) | [3,310 d](/filings/0001099590-26-000006.md) | [3,164](/filings/0001099590-26-000017.md) | [3,696](/filings/0001099590-26-000023.md) | [4,200](/filings/0001099590-25-000051.md) | [4,975 d](/filings/0001099590-26-000006.md) | [4,983](/filings/0001099590-26-000017.md) | [6,010](/filings/0001099590-26-000023.md) |
| Gross profit | $m | [2,095](/filings/0001099590-24-000042.md) | [2,050](/filings/0001099590-24-000042.md) | [2,024](/filings/0001099590-25-000028.md) | [2,365](/filings/0001099590-25-000044.md) | [2,439](/filings/0001099590-25-000051.md) | [2,749 d](/filings/0001099590-26-000006.md) | [2,771](/filings/0001099590-26-000017.md) | [3,094](/filings/0001099590-26-000023.md) | [3,209](/filings/0001099590-25-000051.md) | [3,784 d](/filings/0001099590-26-000006.md) | [3,862](/filings/0001099590-26-000017.md) | [4,159](/filings/0001099590-26-000023.md) |
| Research and development | $m | [396](/filings/0001099590-24-000042.md) | [686](/filings/0001099590-24-000042.md) | [458](/filings/0001099590-25-000028.md) | [460](/filings/0001099590-25-000044.md) | [504](/filings/0001099590-25-000051.md) | [512 d](/filings/0001099590-26-000006.md) | [551](/filings/0001099590-26-000017.md) | [567](/filings/0001099590-26-000023.md) | [567](/filings/0001099590-25-000051.md) | [584 d](/filings/0001099590-26-000006.md) | [699](/filings/0001099590-26-000017.md) | [729](/filings/0001099590-26-000023.md) |
| Operating income | $m | [785](/filings/0001099590-24-000042.md) | [335](/filings/0001099590-24-000042.md) | [528](/filings/0001099590-25-000028.md) | [726](/filings/0001099590-25-000044.md) | [557](/filings/0001099590-25-000051.md) | [820 d](/filings/0001099590-26-000006.md) | [763](/filings/0001099590-26-000017.md) | [825](/filings/0001099590-26-000023.md) | [724](/filings/0001099590-25-000051.md) | [889 d](/filings/0001099590-26-000006.md) | [611](/filings/0001099590-26-000017.md) | [683](/filings/0001099590-26-000023.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [172](/filings/0001099590-24-000042.md) | [65.0](/filings/0001099590-24-000042.md) | [137](/filings/0001099590-25-000028.md) | [137](/filings/0001099590-25-000044.md) | [123](/filings/0001099590-25-000051.md) | [124 d](/filings/0001099590-26-000006.md) | [212](/filings/0001099590-26-000017.md) | [193](/filings/0001099590-26-000023.md) | [215](/filings/0001099590-25-000051.md) | [225 d](/filings/0001099590-26-000006.md) | [162](/filings/0001099590-26-000017.md) | [140](/filings/0001099590-26-000023.md) |
| Net income | $m | [359](/filings/0001099590-24-000042.md) | [165](/filings/0001099590-24-000042.md) | [344](/filings/0001099590-25-000051.md) | [531](/filings/0001099590-25-000051.md) | [397](/filings/0001099590-25-000051.md) | [639 d](/filings/0001099590-26-000006.md) | [494](/filings/0001099590-26-000023.md) | [523](/filings/0001099590-26-000023.md) | [421](/filings/0001099590-25-000051.md) | [559 d](/filings/0001099590-26-000006.md) | [417](/filings/0001099590-26-000023.md) | [466](/filings/0001099590-26-000023.md) |
| Diluted EPS | $ per share | [7.16](/filings/0001099590-24-000042.md) | [3.25](/filings/0001099590-24-000008.md) | [6.78](/filings/0001099590-25-000028.md) | [10.48](/filings/0001099590-25-000044.md) | [7.83](/filings/0001099590-25-000051.md) | not reported | [9.74](/filings/0001099590-26-000017.md) | [10.31](/filings/0001099590-26-000023.md) | [8.32](/filings/0001099590-25-000051.md) | not reported | [8.23](/filings/0001099590-26-000017.md) | [9.19](/filings/0001099590-26-000023.md) |
| Basic EPS | $ per share | [7.18](/filings/0001099590-24-000042.md) | [3.26](/filings/0001099590-24-000008.md) | [6.78](/filings/0001099590-25-000028.md) | [10.48](/filings/0001099590-25-000044.md) | [7.83](/filings/0001099590-25-000051.md) | not reported | [9.74](/filings/0001099590-26-000017.md) | [10.31](/filings/0001099590-26-000023.md) | [8.32](/filings/0001099590-25-000051.md) | not reported | [8.23](/filings/0001099590-26-000017.md) | [9.19](/filings/0001099590-26-000023.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.2](/filings/0001099590-23-000033.md) | [2.6](/filings/0001099590-25-000007.md) | [2.6](/filings/0001099590-24-000017.md) | [2.8](/filings/0001099590-24-000026.md) | [2.2](/filings/0001099590-24-000042.md) | [2.6](/filings/0001099590-26-000006.md) | [3.0](/filings/0001099590-25-000028.md) | [3.0](/filings/0001099590-25-000044.md) | [2.6](/filings/0001099590-25-000051.md) | [3.7](/filings/0001099590-26-000023.md) | [3.7](/filings/0001099590-26-000017.md) | [3.6](/filings/0001099590-26-000023.md) |
| Current assets | $bn | [13.1](/filings/0001099590-23-000033.md) | [14.3](/filings/0001099590-25-000007.md) | [15.5](/filings/0001099590-24-000017.md) | [16.5](/filings/0001099590-24-000026.md) | [17.8](/filings/0001099590-24-000042.md) | [20.1](/filings/0001099590-26-000006.md) | [21.7](/filings/0001099590-25-000028.md) | [26.1](/filings/0001099590-25-000044.md) | [28.8](/filings/0001099590-25-000051.md) | [33.6](/filings/0001099590-26-000023.md) | [37.1](/filings/0001099590-26-000017.md) | [40.8](/filings/0001099590-26-000023.md) |
| Total assets | $bn | [16.1](/filings/0001099590-23-000033.md) | [17.6](/filings/0001099590-25-000007.md) | [19.1](/filings/0001099590-24-000017.md) | [20.0](/filings/0001099590-24-000026.md) | [22.6](/filings/0001099590-24-000042.md) | [25.2](/filings/0001099590-26-000006.md) | [27.7](/filings/0001099590-25-000028.md) | [32.9](/filings/0001099590-25-000044.md) | [36.7](/filings/0001099590-25-000051.md) | [42.7](/filings/0001099590-26-000023.md) | [46.9](/filings/0001099590-26-000017.md) | [51.4](/filings/0001099590-26-000023.md) |
| Current liabilities | $bn | [10.3](/filings/0001099590-23-000033.md) | [11.3](/filings/0001099590-25-000007.md) | [12.3](/filings/0001099590-24-000017.md) | [12.9](/filings/0001099590-24-000026.md) | [14.3](/filings/0001099590-24-000042.md) | [16.6](/filings/0001099590-26-000006.md) | [18.1](/filings/0001099590-25-000028.md) | [21.8](/filings/0001099590-25-000044.md) | [24.5](/filings/0001099590-25-000051.md) | [28.6](/filings/0001099590-26-000023.md) | [32.0](/filings/0001099590-26-000017.md) | [36.4](/filings/0001099590-26-000023.md) |
| Total liabilities | $bn | [13.4](/filings/0001099590-23-000033.md) | [14.5](/filings/0001099590-25-000007.md) | [15.7](/filings/0001099590-24-000017.md) | [16.4](/filings/0001099590-24-000026.md) | [18.6](/filings/0001099590-24-000042.md) | [20.8](/filings/0001099590-26-000006.md) | [22.7](/filings/0001099590-25-000028.md) | [27.2](/filings/0001099590-25-000044.md) | [30.5](/filings/0001099590-25-000051.md) | [35.9](/filings/0001099590-26-000023.md) | [39.7](/filings/0001099590-26-000017.md) | [43.5](/filings/0001099590-26-000023.md) |
| Long-term debt | $bn | [4.5](/filings/0001099590-23-000033.md) | [4.5](/filings/0001099590-25-000007.md) | [4.5](/filings/0001099590-24-000017.md) | [4.6](/filings/0001099590-24-000026.md) | [5.4](/filings/0001099590-24-000042.md) | [5.7](/filings/0001099590-26-000006.md) | [6.4](/filings/0001099590-25-000028.md) | [7.3](/filings/0001099590-25-000044.md) | [7.8](/filings/0001099590-25-000051.md) | [9.2](/filings/0001099590-26-000023.md) | [9.9](/filings/0001099590-26-000017.md) | [10.6](/filings/0001099590-26-000023.md) |
| Shareholders' equity | $bn | [2.7](/filings/0001099590-24-000042.md) | [3.1](/filings/0001099590-26-000006.md) | [3.4](/filings/0001099590-25-000051.md) | [3.7](/filings/0001099590-25-000051.md) | [4.0](/filings/0001099590-25-000051.md) | [4.4](/filings/0001099590-26-000023.md) | [5.0](/filings/0001099590-26-000023.md) | [5.7](/filings/0001099590-26-000023.md) | [6.2](/filings/0001099590-25-000051.md) | [6.7](/filings/0001099590-26-000023.md) | [7.3](/filings/0001099590-26-000023.md) | [7.8](/filings/0001099590-26-000023.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [941 d](/filings/0001099590-24-000042.md) | [1,928 d](/filings/0001099590-26-000006.md) | [1,512](/filings/0001099590-25-000028.md) | [1,882 d](/filings/0001099590-25-000044.md) | [1,600 d](/filings/0001099590-25-000051.md) | [2,924 d](/filings/0001099590-26-000006.md) | [1,031](/filings/0001099590-26-000017.md) | [2,917 d](/filings/0001099590-26-000023.md) | [2,959 d](/filings/0001099590-25-000051.md) | [5,209 d](/filings/0001099590-26-000006.md) | [2,075](/filings/0001099590-26-000017.md) | [3,662 d](/filings/0001099590-26-000023.md) |
| Capital expenditure | $m | [126 d](/filings/0001099590-24-000042.md) | [180 d](/filings/0001099590-24-000008.md) | [146](/filings/0001099590-24-000017.md) | [183 d](/filings/0001099590-24-000026.md) | [222 d](/filings/0001099590-24-000042.md) | [309 d](/filings/0001099590-26-000006.md) | [272](/filings/0001099590-26-000017.md) | [287 d](/filings/0001099590-26-000023.md) | [357 d](/filings/0001099590-25-000051.md) | [427 d](/filings/0001099590-26-000006.md) | [271](/filings/0001099590-26-000017.md) | [441 d](/filings/0001099590-26-000023.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [149 d](/filings/0001099590-24-000042.md) | [0.0 d](/filings/0001099590-26-000006.md) | [0.0](/filings/0001099590-24-000017.md) | [1.0 d](/filings/0001099590-25-000044.md) | [0.0 d](/filings/0001099590-25-000051.md) | [0.0 d](/filings/0001099590-26-000006.md) | not reported | not reported | [1.0 d](/filings/0001099590-25-000051.md) | [0.0 d](/filings/0001099590-26-000006.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.2](/filings/0001099590-24-000017.md) | [51.2](/filings/0001099590-24-000026.md) | [50.2](/filings/0001099590-24-000042.md) | [50.7](/filings/0001099590-24-000008.md) | [50.7](/filings/0001099590-25-000028.md) | [50.7](/filings/0001099590-25-000044.md) | [50.7](/filings/0001099590-25-000051.md) | [50.7](/filings/0001099590-26-000017.md) | [50.7](/filings/0001099590-26-000023.md) | [50.7](/filings/0001099590-25-000051.md) | [50.7](/filings/0001099590-26-000017.md) | [50.7](/filings/0001099590-26-000023.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 50,696,802 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001099590-26-000023.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.